Hirobriz Breezhaler vs Striverdi Respimat: Side-by-Side Comparison
Quick answer: Hirobriz Breezhaler and Striverdi Respimat are both long-acting beta-2 agonist (laba) used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Hirobriz Breezhaler | Striverdi Respimat |
|---|---|---|
| Drug class | Long-acting beta-2 agonist (LABA) | Long-acting beta-2 agonist (LABA) |
| ATC code | R03AC18 | R03AC19 |
| Primary indications | Chronic obstructive pulmonary disease (COPD) | Chronic obstructive pulmonary disease (COPD) |
| Mechanism | Ultra long-acting beta-2 adrenergic receptor agonist causing bronchodilation | Selective long-acting beta-2 adrenergic receptor agonist causing bronchial smooth muscle relaxation |
| Common dose | 150-300 mcg inhaled once daily | 5 micrograms (2 inhalations of 2.5 mcg) once daily via Respimat inhaler |
| Detail page | Hirobriz Breezhaler details → | Striverdi Respimat details → |
How to choose between Hirobriz Breezhaler and Striverdi Respimat
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Long-acting beta-2 agonist (LABA) on iMedic · Hirobriz Breezhaler full details · Striverdi Respimat full details
Frequently asked questions
Is Hirobriz Breezhaler better than Striverdi Respimat?
Neither is universally 'better.' They are both long-acting beta-2 agonist (laba) with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Hirobriz Breezhaler to Striverdi Respimat?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Hirobriz Breezhaler and Striverdi Respimat have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Hirobriz Breezhaler and Striverdi Respimat available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.